Elixiron Immunotherapeutics is a company developing therapeutics for cancer, neurological diseases, and inflammatory disorders.
Aprinoia Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative imaging-based diagnostic tools and therapies for neurological diseases, particularly Alzheimer's disease and tauopathies. Established in 2015 and headquartered in Taipei, Taiwan, with additional facilities in China and Japan, the company specializes in creating diagnostic tracers, including 18F-PM-PBB3 for tau positron-emission tomography (PET) imaging, which aids in identifying tauopathies and supports the development of corresponding treatments. Aprinoia Therapeutics aims to enhance the detection, progression monitoring, and treatment of neurodegenerative conditions such as Alzheimer's, Parkinson's, and dementia through its advanced diagnostic and therapeutic platforms, ultimately striving to improve patient outcomes and brain health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.